Multiple myeloma (MM) is a heterogenous malignant disease. Novel agents including bispecific antibodies and chimeric antigen receptor (CAR) T cells have improved response rates and patient outcome, but the majority of patients ultimately still relapse. High dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HCT) remains standard care of treatment for transplant-eligible patients. While single auto-HCT is commonly used, a planned tandem auto-HCT or auto-allo approach remains controversial, based on conflicting results from clinical trials. Here we compared the outcome of 24,936 MM patients aged between 20 and 65 years who underwent first auto-HCT during 2002-2015, reported to the EBMT registry, of whom 3683 and 878 got tandem auto-HCT and auto-allo-HCT respectively. We used non-standard statistical approaches to account for time-dependence of treatments and of their effects, including models with multiple timescales and dynamic prediction. Differences were reported by graphs of hazard functions, hazard ratios and conditional probabilities over time. For both OS and PFS, there was a limited but persistent advantage for the tandem auto-HCT group compared to single auto-HCT, and a clear advantage for the auto-allo-HCT group over both other strategies in the longer term, albeit at the cost of higher early mortality.

Ankara Liv Hospital Istinye University Ankara Turkey

Birmingham Centre for Cellular Therapy and Transplant Birmingham United Kingdom

Christie Hospital Manchester Manchester United Kingdom

CHU de Lille Univ Lille INSERM U1286 Infinite Lille France

CHU Nantes Nantes France

Dél pesti Centrumkórház Budapest Hungary

Department of Haematology Trinity College Dublin St James's Hospital Dublin Ireland

Department of Haematology University College London Hospitals NHS Trust London UK

EBMT Leiden Study Unit Leiden the Netherlands

Erasmus MC Cancer Institute Rotterdam Netherlands

Kings College Hospital London London United Kingdom

Newcastle upon Tyne Hospitals Newcastle United Kingdom

Oslo University Hospital Rikshospitalet Oslo Norway

Royal Marsden Hospital London United Kingdom

Sapienza University of Rome Rome Italy

St Bartholomew's Hospital London London United Kingdom

Transplantation and Cellular Therapy Department of Hematology Institut Paoli Calmettes Management Sport Cancer Lab Luminy Aix Marseille University Marseille France

University Clinical Centre Medical University of Warsaw Warsaw Poland

University Hospital Brno Brno Czech Republic

University Hospital Eppendorf Hamburg Germany

University Hospital of Heidelberg Medical Department 5 Heidelberg Germany

University of Muenster Muenster Germany

VU University Medical Center Amsterdam Netherlands

See more in PubMed

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25:1003–14. PubMed

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20. PubMed PMC

Rees MJ, D’Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies. Am Soc Clin Oncol Educ Book. 2024;44:e433520. PubMed

Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10:17. PubMed PMC

Rodriguez-Otero P, San-Miguel JF. Cellular therapy for multiple myeloma: what’s now and what’s next. Hematology Am Soc Hematol Educ Program. 2022;2022:180–9. PubMed PMC

Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. Blood Adv. 2023;7:1056–64. PubMed

Beksac M, Hayden P. Upfront autologous transplantation still improving outcomes in patients with multiple myeloma. Lancet Haematol. 2023;10:e80–e82. PubMed

Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12:1195–203. PubMed PMC

Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, et al. Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 trial. Biol Blood Marrow Transplant. 2020;26:798–804. PubMed

Chen YH, Fogel L, Sun AY, Yang C, Patel R, Chang WC, et al. The efficacy and safety of tandem transplant versus single stem cell transplant for multiple myeloma patients: a systematic review and meta-analysis. Diagnostics. 2024;14:1030. PubMed PMC

Grieb N, Oeser A, Ferle M, Hanke F, Flossdorf S, Sauer S, et al. German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST). Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant. 2024. https://doi.org/10.1038/s41409-024-02490-1 . PubMed DOI PMC

Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502. PubMed

Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434–41. PubMed

Mai EK, Benner A, Bertsch U, Brossart P, Hänel A, Kunzmann V, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173:731–41. PubMed

Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456–68. PubMed

Gahrton G, Iacobelli S, Garderet L, Yakoub-Agha I, Schönland S. Allogeneic transplantation in multiple myeloma—does it still have a place? J Clin Med. 2020;9:2180. PubMed PMC

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121:5055–63. PubMed

Iacobelli S, De Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, et al. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplant. 2015;50:505–10. PubMed

Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, et al. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transpl. 2020;55:1810–6.

de Wreede LC, Schetelig J, Putter H. Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions. Bone Marrow Transplant. 2022;57:1428–34. PubMed

Efron B. The two-way proportional hazards model. J R Stat Soc Ser B. 2002;64:899–909.

Van Houwelingen HC, Putter H. Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data. Lifetime Data Anal. 2008;14:447–63. PubMed PMC

Lawless S, Iacobelli S, Knelange NS, Chevallier P, Blaise D, Milpied N, et al. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling. Haematologica. 2023;108:1105–14. PubMed

Larsen JT. Think twice: doubling back to tandem autologous stem cell transplant in newly diagnosed multiple myeloma with extramedullary disease. Biol Blood Marrow Transplant. 2019;25:e317–18. PubMed

Wei M, Xie C, Huang J, Liu Q, Lai Y. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis. Hematology. 2023;28:2269509. PubMed

Gagelmann N, Eikema D-J, Koster L, Caillot D, Pioltelli P, Lleonart JB, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2134–42. PubMed

Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, et al. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study. Haematologica. 2024;109:1469–79. PubMed

Huo L, Magliano DJ, Rancière F, Harding JL, Nanayakkara N, Shaw JE, et al. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011. Diabetologia. 2018;61:1055–63. PubMed

Albrektsen G, Heuch I, Hansen S, Kvåle G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer. 2005;92:167–75. PubMed

Commenges D, Joly P, Letenneur L, Dartigues JF. Incidence and mortality of Alzheimer’s disease or dementia using an illness-death model. Stat Med. 2004;23:199–210. PubMed PMC

Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age–period and age–cohort models. Stat Med. 1987;6:449–67. PubMed

Iacobelli S, Carstensen B. Multiple time scales in multi-state models. Stat Med. 2013;32:5315–27. PubMed